Effect of two doses of a mixture of soluble fibres on body weight and metabolic variables in overweight or obese patients: a randomised trial

Jordi Salas-Salvadó1*, Xavier Farrés2, Xavier Luque3, Silvia Narejos4, Manel Borrell5, Josep Basora6, Anna Anguera7, Ferran Torres8, Mónica Bulló1 and Rafel Balanza1, for the Fiber in Obesity-Study Group†

1Human Nutrition Unit, Facultat de Medicina i Ciències de la Salut, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, CSant Llorenç 21, 43201 Reus, Spain
2Centre d’Atenció Primària el Remei de Vic, Servei Català de la Salut, Barcelona, Spain
3Centre d’Atenció Primària d’Alcover, Servei Català de la Salut, Barcelona, Spain
4Centre d’Atenció Primària de Centelles, Servei Català de la Salut, Barcelona, Spain
5Centre d’Atenció Primària Sarrià, Servei Català de la Salut, Barcelona, Spain
6Centre d’Atenció Primària Reus I, Institut Català de la Salut, Reus, Spain
7Research Department, Madaus, S.A., Barcelona, Spain
8Laboratorio de Bioestadística y Epidemiología, Servei de Farmacología Clínica, Hospital Clínic, Universitat Autònoma de Barcelona, Barcelona, Spain

(Received 28 May 2007 – Revised 23 October 2007 – Accepted 25 October 2007 – First published online 22 November 2007)

The aim of the study was to compare the effect of the administration of a mixture of fibres on body weight-loss, satiety, lipid profile and glucose metabolism. We included 200 overweight or obese patients in a parallel, double-blind, placebo-controlled clinical trial, who were randomised to receive, in the context of an energy-restricted diet for a period of 16 weeks, a mixed fibre dose (3 g Plantago ovata husk and 1 g glucomannan) twice (b.i.d. group) or three times daily (t.i.d. group) or placebo. Weight change was the primary efficacy endpoint. Satiety, dietary compliance, lipid profile, glucose tolerance, insulin resistance and high-sensitivity C-reactive protein were secondary endpoints. Weight loss tended to be higher after both doses of fibre (−4·52 (SD 0·56) and −4·60 (SD 0·55) kg) than placebo (−0·79 (SD 0·58) kg); the differences in changes between groups were not statistically significant. Postprandial satiety increased in both fibre groups compared to the placebo. The differences between groups in LDL-cholesterol levels were significant (P = 0·03), with greater reductions in the two fibre-supplemented groups (−0·38 (SD 0·10) and −0·24 (SD 0·09) mmol/l in the b.i.d. and t.i.d. groups v. +0·06 (SD 0·09) mmol/l in placebo group). A similar pattern was observed for changes in total cholesterol: LDL-cholesterol and HDL-cholesterol:LDL-cholesterol ratios were not significant. Interventions were well tolerated and had no effects on HDL-cholesterol, glucose and insulin concentrations, glucose tolerance or high-sensitivity C-reactive protein. In conclusion, a 16-week dietary supplement of soluble fibre in overweight or obese patients was well tolerated, induced satiety and had beneficial effects on some CVD risk factors, the most important of which was a significant decrease in plasma LDL-cholesterol concentrations.

Dietary fibre: Glucomannan: Plantago: Body weight: Lipid profile

Excess energy intake is the primary dietary cause of obesity, although other dietary factors need to be taken into account. Nutritional guidelines recommend dietary fibre for health promotion and disease prevention. However, the beneficial effects of dietary fibre in the prevention, or treatment, of obesity and associated metabolic disturbances are not consistent. Obesity and diabetes are less prevalent in populations consuming large amounts of dietary fibre. Further, excess weight and obesity were substantially lower in vegetarian populations(1), suggesting that fibre intake could play an important role in the prevention and progression of these metabolic conditions. Cross-sectional studies have shown that, following adjustment for confounding variables, the intakes of total fibre and soluble fibre are inversely related to total fat intake, body-fat content and BMI. Obese subjects typically consume less fibre than normal-weight individuals(2). In a 10-year prospective study in young adults, fibre intake was associated with lower weight increases and a lower risk of developing obesity, after adjustment for fat intake(3). Several mechanisms have been proposed to explain the role of fibre intake on body-weight regulation(4), apart from displacing energy and nutrients from the diet. Fibre increases the volume of gastric contents, reduces gastric emptying and promotes satiation(5,6) while decreasing the absorption of

Abbreviations: b.i.d., experimental treatment with mixed fibre dose given twice daily; t.i.d., experimental treatment with mixed fibre dose given three times daily; HOMA-IR, homeostasis model assessment of insulin resistance; ITT, intention-to-treat; OGTT, oral glucose tolerance test.

* Corresponding author: Dr J. Salas-Salvadó, fax +34 977 75 93 22, email jordi.salas@urv.cat
† The investigators participating in the Fiber in Obesity-Study Group are listed in the Acknowledgements.
Fibre, body weight and metabolic variables

Macronutrients(7) and influencing the secretion of gut hormones controlling fat oxidation and storage(8).

Epidemiological data and mechanistic studies support the beneficial effects of fibre in body-weight regulation, but data from randomised controlled clinical trials evaluating the effect of fibre supplementation of the diet on body weight have not been consistent(9–12). In a systematic review, Howarth et al. analysed several clinical trials conducted in small and heterogeneous population samples over relatively short periods of time(13). The findings were that the intake of 12 g fibre/d resulted in a decrease of 10% in energy intake and a body-weight loss of 1.9 kg over 3.8 months. These authors indicated that this effect on body-weight loss was greater in obese subjects.

However, long-term compliance to fibre supplementation of the diet is poor in adults(14). If fibre is to be considered a long-term therapeutic option, an effective and well-tolerated source needs to be found.

The aim of our study was to evaluate the effect of a 16-week consumption of a new fibre mixture on weight loss, tolerance, satiety, the lipid profile, glucose metabolism and high-sensitivity C-reactive protein in overweight (or obese) patients attending primary care centres.

Material and methods

Subjects

Male and female patients between the ages of 18 and 70 years who were overweight or obese (27 < BMI < 35 kg/m²) with a high degree of motivation to achieve weight loss were invited to participate in a parallel, double-blind, randomised placebo-controlled, multi-centred clinical trial using two dose levels of a mixture of fibre. Patients were recruited from eleven primary care centres in Spain. Exclusion criteria for the study were: (1) diabetes mellitus requiring treatment with anti-diabetic drugs or insulin, or other known endocrine disorders; (2) dyslipidaemia requiring pharmacological treatment according to the National Cholesterol Education Program Adult Treatment Panel III (ATP III) guidelines; (3) intake of anti-obesity medication and/or following a low-energy diet over the 8 weeks prior to entry into the present study; (4) previous bariatric surgery; (5) history of eating disorders; (6) intake of dietary fibre supplements in the month prior to inclusion in the present study; (7) acute or chronic infection, inflammatory disease or cancer. The Institutional Review Board of the eleven participating primary care centres approved the study protocol. Written informed consent was obtained from all patients participating in the study.

Study design and intervention

At the initial visit, a complete medical history and physical examination of the patient was taken. Before randomisation the subjects were stratified by gender and BMI (BMI ≤ 30 kg/m² or BMI > 30 kg/m²). Eligible subjects were assigned to receive fibre (at two fixed doses) or placebo in a 2:1 ratio for each dose level for a 16-week period. A randomisation list was computer generated in a fixed block size of six patients. The details of the randomisation codes were kept in sealed envelopes away from the investigator. Only in cases of the utmost necessity (e.g. serious adverse events) was the assignment of the patient made known to the investigator by the study co-ordinator. Patients, investigators, monitors and statisticians were blinded with respect to the treatment assignment.

All enrolled patients were individually advised to follow a diet that was reduced by 2.5 MJ/d compared to their current diet, as recommended by the National Heart Lung and Blood Institute(15) and the Spanish Consensus on obesity (<35, >45 and <25% of total energy intake in the form of fat, carbohydrates and protein respectively)(16). No participant received a diet containing <4.1 MJ/d during the course of the study. Depending on the assigned group, the patients received either a fibre-mix product, or a placebo product twice daily (b.i.d.) or three times daily (t.i.d.), taken with 150 ml water 10 min before lunch and dinner (b.i.d. group) or breakfast, lunch and dinner (t.i.d. group), respectively.

The fibre supplement and the placebo were administered as soluble effervescent powder in sachets (manufactured by Madaus, S.A.) of identical weight and presentation. Each sachet of the fibre supplement contained 3 g Plantago ovata seed husks and 1 g glucosamin. The placebo sachets contained 3 g microcrystalline cellulose.

Measurements

With the patient wearing light clothes, weight was measured with a ±100 g precision at baseline and every 4 weeks until the study was completed. Weight difference between baseline and final visit was considered the primary efficacy endpoint. Other variables measured at baseline and after 16 weeks of treatment were self-assessment of satiety and adherence to diet and treatment, lipid profile (total cholesterol, VLDL-, LDL- and HDL-cholesterol and TAG), fasting glucose and insulin, oral glucose tolerance test (OGTT), homeostasis model assessment of insulin resistance (HOMA-IR) index, fasting glycosylated Hb and serum high-sensitivity C-reactive protein.

At baseline, and after 8 and 16 weeks of treatment, patients were asked to determine and record in a diary, the level of postprandial satiety on the day of the consultation visit plus 2d prior to the visit, on a 100 mm visual analogue scale. In the same diary, the patient recorded the self-assessment of level of adherence to the diet on a 100 mm visual analogue scale. The investigator monitored treatment compliance by counting the medication sachets returned by the patient at each follow-up visit at weeks 4, 8, 12 and 16.

Fasting blood samples were taken between 08.00 and 09.00 hours at baseline and at the end of the study. Biochemical parameters were assessed by routine methods. Fasting insulin was centrally measured by radioimmunosassay using a commercial kit (Immundiagnostik AG, Bensheim, Germany). The lower limit of detection was 0.1 mg/l and the intra- and inter-assay CV were 0.9 and 1.7%, respectively. Insulin resistance was assessed by HOMA-IR as follows: fasting plasma insulin (mIU/l) x the fasting plasma glucose (mmol/l) divided by 22.5. Serum high-sensitivity C-reactive protein concentrations were also centrally measured using commercial enzyme-linked immunosorbent assay kits (Alpha Diagnostic International, Texas, USA). Intra- and inter-assay CV were <10%. OGTT was performed following a 75 g glucose load.
in fasting conditions at baseline and after 16 weeks of treatment.

Information on adverse events possibly related to the dietary supplement products was solicited at each visit to the clinic during the study period. At each visit the patients were asked an open-ended question regarding any unusual symptoms, or discomfort, or side effects such as more defaecation, flatulence, or any other events over the previous weeks.

**Statistical methods**

Based on 80% power to detect a significant difference of 1.5 (SD 0.56) kg in weight reduction, type 1 error (α) = 0.05 (two-sided), fifty-one valid patients were required for each study group. We randomised a total of 200 patients to compensate for non-measurable patients. Of the 200 randomised patients, 185 were included in the safety analysis, 166 in the intention-to-treat (ITT) analysis, and 126 in the per-protocol analysis. The results are expressed as mean, standard deviation and/or 95% CI, or as a percentage. The primary and secondary efficacy variables were evaluated by an ANCOVA model using the baseline value and the BMI stratum as covariates. Between-groups comparisons for the rest of the variables were performed using the Fisher exact test or ANOVA, according to the nature of the variables. The last-observation-carry-forward approach was applied for the main outcome; the rest of variables were analysed according to the available-data-only approach. The analysis was performed following the ITT principle, using SAS version 9.1.3 software (SAS Institute Inc., Cary, NC, USA), and the level of significance was established at \( P = 0.05 \) (two-sided). We show the results of the ITT analysis because no significant differences in the results were found between the ITT and the per-protocol analysis.

### Results

#### Patients

Two hundred adult patients were randomised and assigned to the three treatment groups (t.i.d. group, n=68; b.i.d. group, n=66; placebo group, n=66). Of these, thirty-three patients were not included in the ITT analysis: nine due to withdrawal of informed consent, five due to selection criteria violation, and nineteen due to the lack of some measurable variables at baseline or due to other reasons. Subsequent data refers only to the 166 patients of the ITT study population (t.i.d. group, n=58; b.i.d. group, n=53; placebo group, n=55). There were no statistically significant differences among treatment groups with respect to time-on-treatment or causes for discontinuing the study. Table 1 summarises the baseline characteristics of the 166 measurable patients (22% men and 78% women). The three groups were well balanced in terms of age, gender, weight and BMI. No significant differences were observed between groups in relation to the plasma lipid profile, fasting glucose, insulin or glycosylated Hb concentrations or glucose tolerance at the beginning of the study. None of the groups showed significant differences in relation to the degree of postprandial satiety.

Adherence to the treatment (monitored by the investigator by counting the medication sachets returned by the patient at each follow-up visit) and to the diet (evaluated by the patient on the visual analogue scale at each follow-up visit) were found among groups in relation to treatment compliance or to the self-assessment of the level of adherence to the diet.

#### Changes produced following the intervention

Weight loss was observed with both fibre doses (−4.52 (SD 0.56) kg in the b.i.d. group and −4.60 (SD 0.55) kg in the t.i.d. group) at each follow-up visit. There were no significant differences between groups at each follow-up visit in all the groups was, in general, very high (>90% in all the consultation visits). No statistically significant differences were found among groups in relation to treatment compliance or to the self-assessment of the level of adherence to the diet.

### Table 1. Characteristics of the subjects on entry into the trial

<table>
<thead>
<tr>
<th></th>
<th>b.i.d. group (n=53)</th>
<th>t.i.d. group (n=58)</th>
<th>Placebo (n=55)</th>
<th>Total (n=166)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Men (%)</td>
<td>47·1 (12·5)</td>
<td>50·1 (11·6)</td>
<td>46·4 (11·9)</td>
<td>47·9 (12·0)</td>
</tr>
<tr>
<td>Women (%)</td>
<td>79·2 (20·8)</td>
<td>79·3 (20·7)</td>
<td>76·4 (23·6)</td>
<td>78·3 (21·7)</td>
</tr>
<tr>
<td><strong>Weight (kg)</strong></td>
<td>79·7 (11·0)</td>
<td>80·6 (11·3)</td>
<td>83·7 (11·6)</td>
<td>81·3 (11·3)</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>31·2 (2·3)</td>
<td>31·0 (2·4)</td>
<td>31·2 (2·3)</td>
<td>31·2 (2·3)</td>
</tr>
<tr>
<td><strong>HDL-cholesterol:LDL-cholesterol</strong></td>
<td>0·40 (0·16)</td>
<td>0·42 (0·18)</td>
<td>0·43 (0·16)</td>
<td>0·42 (0·17)</td>
</tr>
<tr>
<td><strong>Total cholesterol:LDL-cholesterol</strong></td>
<td>4·3 (1·1)</td>
<td>4·2 (1·1)</td>
<td>4·1 (1·4)</td>
<td>4·2 (1·2)</td>
</tr>
<tr>
<td><strong>Fasting glucose (mmol/l)</strong></td>
<td>5·6 (1·2)</td>
<td>5·4 (1·9)</td>
<td>5·4 (2·1)</td>
<td>5·5 (2·0)</td>
</tr>
<tr>
<td><strong>Glucose 2 h OGTT (mmol/l)</strong></td>
<td>0·86 (0·5)</td>
<td>1·63 (0·6)</td>
<td>1·64 (1·27)</td>
<td>1·92 (1·83)</td>
</tr>
<tr>
<td><strong>hs-CRP (mg/l)</strong></td>
<td>0·75 (0·5)</td>
<td>0·86 (0·5)</td>
<td>0·75 (0·5)</td>
<td>0·77 (0·88)</td>
</tr>
</tbody>
</table>

b.i.d., mixed fibre dose given twice daily; t.i.d., mixed fibre dose given three times daily; OGTT, oral glucose tolerance test; HOMA-IR, homeostasis model assessment of insulin resistance; hs-CRP, high-sensitivity C-reactive protein.

* There were no significant differences between groups.
the t.i.d. group) and with the placebo (−3.79 (SD 0.58) kg) at
the end of 16 weeks of the study. The weight loss was pro-
gressive and constant in the three study groups, without any
weight regained at the end of the study. Although the changes
tend to be greater in both groups supplemented with dietary
fibre, the differences between groups were not statistically
significant (P=0.43) (Fig. 1).

Table 2 summarises the effect of interventions on the
measured plasma biochemical parameters. During the 16
weeks of the trial, glycosylated Hb decreased within all
three groups (−0.03 (SD 0.06) in the b.i.d. group, −0.11 (SD
0.06) in the t.i.d. group and −0.15 (SD 0.06) in the placebo
group); the differences between the groups not being
statistically significant. Fasting glucose and 2 h post-OGTT
decreased within all three groups with the exception of the
fasting glucose in the placebo group (fasting glucose changed
−0.12 (SD 0.11), −0.09 (SD 0.10), 0.03 (SD 0.10) mmol/l and
0.03 (SD 0.10) mmol/l in the b.i.d. and t.i.d. and place-
bo groups, respectively). Fasting insulin and 2 h post-OGTT
decreased considerably within the b.i.d. group, albeit the
changes between groups were not statistically significant.
No significant differences in changes on HOMA-IR index were
observed among the groups. However, the changes in the
lipid profile induced by the interventions were different
between groups. The decrease in plasma total cholesterol
tended to be greater in the b.i.d. and t.i.d. groups compared
to placebo. The differences between groups with respect to
the plasma LDL-cholesterol concentrations were statistically
significant (P=0.03), with a greater decrease observed in the
two fibre-supplemented groups (−0.38 (SD 0.10) and −0.24
(SD 0.09) mmol/l in the b.i.d. and t.i.d. groups vs. −0.06
(SD 0.09) mmol/l in placebo), although no dose–response pat-
tern was observed for this parameter. The changes in HDL-
cholesterol and TAG concentrations did not follow any clear
trend within or between the intervention groups. The dif-
ferences between groups in the plasma total cholesterol:HDL-
cholesterol and HDL-cholesterol:LDL-cholesterol ratio were
statistically significant (P=0.03 and P=0.02, respectively,
with a greater change observed in the two fibre-supplemented
groups). No differences between groups were observed in
relation to serum C-reactive protein concentrations. Table 3
summarises the observed effects of the 16-week fibre sup-
plementation on perceived satiety. The differences between
groups in changes in satiety were statistically significant
post-lunch (P=0.04) but not post-dinner. However, no signifi-
cant differences in satiety were observed between the two
fibre-supplemented groups.

Safety

No serious adverse event was reported during the study. No
significant differences in total adverse events were observed
between groups. Gastrointestinal complaints (3.8% diarrhoea,
32.2% flatulence, 2.2% constipation, 2.2% upper abdominal
pain and 0.5% abdominal distension) were the most fre-
cently reported adverse events, with no significant differ-
ces in the proportions of these events reported between
the treatment groups. There were no patient withdrawals
from the study due to adverse events.

Discussion

The results of our study suggest that fibre supplementation, in
the context of a weight-reducing diet, could be beneficial in
overweight or obese individuals because the additional fibre
induces satiety and a more long-term favourable lipoprotein
profile than placebo. However, the present results do not sup-
port the hypothesis that fibre supplements in combination with
a conventional energy intake restriction can have additional
effects on weight reduction and glucose tolerance.

The literature contains several reports of the effect of fibre
supplements on body weight. However, in few of the ran-
domised placebo-controlled clinical trials has the body weight
been considered the primary variable in the analysis. In
addition, long-term (≥4 months) trials are rare and have been
conducted in small samples of heterogeneous popu-
lations (healthy controls, obese or diabetic patients) while
using different types and doses of fibre.

To the best of our knowledge, our study is unique in analys-
ing the effect of two doses of soluble-fibre supplementation on
body weight and/or other metabolic variables. Because of
the great variability expected in the response of body weight
following intervention, our study was performed in 200
individuals. Hence, the present study is one of the few
large-scale studies analysing the long-term effects of a sup-
plement of fibre on lipid profile, glucose tolerance, and
weight changes and satiety.

The influence of dietary-fibre supplements on energy
regulation remains controversial. One of the best-studied
supplements of fibre on body weight is guar gum. A meta-
analysis of the randomised placebo-controlled trials identified
thirty-four guar gum trials of which only eleven could be ana-
lysed and only two were for a period >14 weeks. The
meta-analysis concluded that guar gum is not efficacious for
reducing body weight and is frequently associated with gastro-
intestinal complaints such as flatulence, diarrhoea, abdominal
pain, and cramps.
Other types of fibre supplements have been studied, also with inconclusive results with respect to weight control\(^{22–24}\). Among these fibres, Plantago ovata and glucomannan are the most relevant. As with the results of our study, a previous large-scale study performed with ispaghula husk showed no significant short-term (3 weeks) differences in body-weight loss when comparing ispaghula, bran and control groups\(^{22}\). Also as with the present study, a decrease in hunger ratings

<table>
<thead>
<tr>
<th>Table 2. Effects of 16-week fibre supplementation on plasma metabolic markers*</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Values are means with standard deviations and means with 95% CI)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Change† (n 166)</th>
<th>Differences‡</th>
<th>P§</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>sd</td>
<td>Mean</td>
</tr>
<tr>
<td>Glycosylated Hb (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·03</td>
<td>0·06</td>
<td>0·12</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·11</td>
<td>0·06</td>
<td>0·04</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·15</td>
<td>0·06</td>
<td></td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·12</td>
<td>0·11</td>
<td>–0·15</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·09</td>
<td>0·10</td>
<td>–0·12</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·03</td>
<td>0·10</td>
<td></td>
</tr>
<tr>
<td>Glucose 2 h OGTT (mmol/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·20</td>
<td>0·29</td>
<td>0·04</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·17</td>
<td>0·28</td>
<td>0·07</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·24</td>
<td>0·27</td>
<td></td>
</tr>
<tr>
<td>Fasting insulin (pmol/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>22·04</td>
<td>7·24</td>
<td>10·20</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>11·26</td>
<td>6·76</td>
<td>0·59</td>
</tr>
<tr>
<td>Placebo group</td>
<td>11·85</td>
<td>6·57</td>
<td></td>
</tr>
<tr>
<td>Insulin 2 h OGTT (pmol/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>41·06</td>
<td>26·37</td>
<td>28·37</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>15·79</td>
<td>24·65</td>
<td>3·10</td>
</tr>
<tr>
<td>Placebo group</td>
<td>12·69</td>
<td>24·65</td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·71</td>
<td>0·23</td>
<td>0·40</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·42</td>
<td>0·21</td>
<td>0·11</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·31</td>
<td>0·30</td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·43</td>
<td>0·12</td>
<td>0·32</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·33</td>
<td>0·11</td>
<td>0·22</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·11</td>
<td>0·11</td>
<td></td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·38</td>
<td>0·10</td>
<td>0·32</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·24</td>
<td>0·09</td>
<td>0·18</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·06</td>
<td>0·09</td>
<td></td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·01</td>
<td>0·04</td>
<td>0·05</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·06</td>
<td>0·03</td>
<td>0·01</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·05</td>
<td>0·03</td>
<td></td>
</tr>
<tr>
<td>Total cholesterol:HDL-cholesterol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·36</td>
<td>0·14</td>
<td>0·44</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·13</td>
<td>0·12</td>
<td>0·21</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·07</td>
<td>0·12</td>
<td></td>
</tr>
<tr>
<td>HDL-cholesterol:LDL-cholesterol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·06</td>
<td>0·02</td>
<td>0·06</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·02</td>
<td>0·02</td>
<td>0·02</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·01</td>
<td>0·02</td>
<td></td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·03</td>
<td>0·26</td>
<td>0·36</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·01</td>
<td>0·23</td>
<td>0·32</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·33</td>
<td>0·23</td>
<td></td>
</tr>
<tr>
<td>hs-CRP (mg/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>0·10</td>
<td>0·15</td>
<td>0·12</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>0·08</td>
<td>0·10</td>
<td>0·10</td>
</tr>
<tr>
<td>Placebo group</td>
<td>0·02</td>
<td>0·05</td>
<td></td>
</tr>
</tbody>
</table>

b.i.d., mixed fibre dose given twice daily; t.i.d., mixed fibre dose given three times daily; OGGT, oral glucose tolerance test; HOMA-IR, homeostasis model assessment of insulin resistance.

* Results from the ANCOVA model. All results are adjusted by stratum and baseline values.
† Changes between start and end of study.
‡ Differences in changes between groups (b.i.d. and t.i.d. v. placebo).
§ Statistical differences in changes between groups.
was observed at the end of the study period compared to the baseline values in both groups receiving the fibre supplements\(^{22}\). No significant short-term effects (6 weeks) of 5 g *Plantago psyllium* on body weight had been observed in type II diabetic patients when evaluating the lipid- and glucose-lowering efficacy of this type of fibre\(^{10}\). In contrast, several studies have demonstrated a significant effect of glucosamann supplements on appetite and body weight. However, only some of these studies were randomised placebo-controlled trials, and all were short-term and performed in small study populations\(^{24–27}\). In our study, the two groups receiving the dietary fibre tended towards greater weight loss than did control individuals. However, the lack of significant differences in body-weight loss observed between groups does not support the hypothesis that this type of fibre has any effect on body weight. Whether significant differences would be observed by increasing the fibre dose is worth considering in future studies.

As with guar gum, isphagula husk (another viscous soluble fibre), has also been associated with gastrointestinal secondary adverse effects because of the rapid fermentation when the fibres arrive intact in the colon\(^{10}\). In a previous study, we observed that a mixture of *Plantago ovata* combined with glucomannan slows fermentation in the colon and retards the rate of butyrate and propionate production *in vitro* (L. Fluvia and A. Anguera, unpublished results). For this reason, we propose that the intake of this fibre mixture increases subject compliance due to fewer gastrointestinal side effects associated with the delay in gas production, which increases the patient’s tolerance of the mixture. It is for this reason that we selected to study the effects of a mixture of these two types of fibre: *Plantago ovata* husks and glucomannan. In the present study the dietary fibre supplement was well tolerated by the patients. Gastrointestinal symptoms were the most frequent adverse events reported in our study but these were not of any clinical significance. Also, there were no significant differences observed between the groups taking the fibre and the placebo group. As such, our study suggests that long-term administration of *Plantago ovata* and glucomannan has a high patient-acceptability.

With respect to changes in the lipid profile, our results are in the same direction of a previously-published meta-analysis analysing this effect. We observed a greater decrease in plasma total cholesterol in both groups of patients receiving the fibre. These differences were due, in part, to significant decreases in the plasma LDL-cholesterol concentrations observed in the two groups receiving the fibre compared to the placebo group (−0.38 (SD 0.10) and −0.24 (SD 0.09) mmol/l in the b.i.d. and t.i.d. groups, respectively). The hypocholesterolaemic effect observed was modest, not dependent on the dose administered, and of the same magnitude as that observed in a meta-analysis where the decrease in total and LDL-cholesterol was estimated to be about 0.05 mmol/l for every gram of soluble fibre added to the diet\(^{23,28}\). As with the conclusions of the meta-analysis cited earlier, our study suggests that the intake of a fibre supplement has no effect on HDL-cholesterol or TAG concentrations. Of note is that obesity is associated with atherogenic dyslipidaemia, which has been considered an important CVD risk factor. Hence, fibre supplementation in the context of a weight-reducing diet could decrease the cardiovascular risk in obese people through the mechanism of LDL-cholesterol reduction i.e. 1 % decrease in plasma LDL-cholesterol is estimated to result in a 2 % decrease in coronary disease mortality. Our results highlight significant differences between groups in relation to the changes in the plasma total cholesterol:HDL-cholesterol and LDL-cholesterol:HDL-cholesterol ratios with more favourable changes induced in the two fibre-supplemented groups compared to placebo.

In relation to glucose metabolism, population studies have shown that high-fibre diets may play a protective role in the prevention of type 2 diabetes\(^{29,30}\) and CVD\(^{31}\). Diets that are high in complex carbohydrates and fibre were shown to be associated with greater insulin sensitivity and a reduction in plasma insulin levels. Also, high-fibre diets contribute to a better metabolic control in diabetic subjects\(^{32}\). However, some clinical studies have shown that only the viscous variety of some soluble fibres play a significant role in reducing postprandial glycaemia\(^{33}\). In our study, the fibre supplements showed no significant effects on insulin resistance, fasting glucose and post-OGTT glucose or insulin concentrations, or glycosylated Hb. This is probably because none of the patients studied had diabetes requiring oral antidiabetic drugs or insulin.

There is a lack of consensus in the literature with regard to the anti-inflammatory effects of fibre. Results from two epidemiological studies indicated that dietary-fibre intake was inversely associated with serum C-reactive protein concentrations\(^{34,35}\), but another large study failed to find any association between whole-grain intake and plasma C-reactive protein, IL-6 or fibrinogen concentrations\(^{36}\). In our study, we were unable to demonstrate any effect of the additional dietary fibre consumption on plasma high-sensitivity C-reactive protein concentrations, although patients receiving the fibre tended to have greater decreases in this parameter.

In conclusion, the present study shows that the administration over a protracted period of 16 weeks of a supplement of a soluble fibre mixture of *Plantago ovata* and glucomannan to overweight or obese patients induced satiety and a decrease in plasma LDL-cholesterol concentrations, without any effect observed on body weight, TAG, HDL-cholesterol concentrations or other glucose metabolism parameters.

### Table 3. Effects of 16-week fibre supplementation on satiety

(Values are means with standard deviations and means with 95 % CI)

<table>
<thead>
<tr>
<th></th>
<th>Change† (n 166)</th>
<th>Differences‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td>Satiety post-lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>5:14</td>
<td>4:53</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>1:07</td>
<td>4:17</td>
</tr>
<tr>
<td>Placebo group</td>
<td>−8:43</td>
<td>4:29</td>
</tr>
<tr>
<td>Satiety post-dinner</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.i.d. group</td>
<td>2:54</td>
<td>4:81</td>
</tr>
<tr>
<td>t.i.d. group</td>
<td>1:06</td>
<td>4:43</td>
</tr>
<tr>
<td>Placebo group</td>
<td>−7:87</td>
<td>4:57</td>
</tr>
</tbody>
</table>

b.i.d., mixed fibre dose given twice daily; t.i.d., mixed fibre dose given three times daily.
† Changes from the ANCOVA model. All results are adjusted by stratum and baseline values.
‡ Differences in changes between groups (b.i.d. and t.i.d. v. placebo).
§ Statistical differences in changes between groups.
Acknowledgements

This study was supported by MADAUS, S.A. and by the Instituto de Salud Carlos III (Thematic Network G03/140 and RD06/0045, and PI051839), Spain. Dr Salas-Salvadó and Dr Ferrán Torres have received consulting or lecture fees from Madaus Laboratories. Dr Anguera belongs to Madaus Laboratory. The order in which the authors has been listed has been agreed on by the investigators. Jordi Salas-Salvadó, Rafel Balanza, Mónica Bulló, Ferrán Torres and Anna Anguera have made the greatest contribution, and wrote the preliminary version. All the authors have contributed equally to the work by discussing and analysing the data and writing the definitive version.


References